Skip to main content

Envisioning is an emerging technology research institute and advisory.

LinkedInInstagramGitHub

2011 — 2026

research
  • Reports
  • Newsletter
  • Methodology
  • Origins
  • Vocab
services
  • Research Sessions
  • Signals Workspace
  • Bespoke Projects
  • Use Cases
  • Signal Scanfree
  • Readinessfree
impact
  • ANBIMAFuture of Brazilian Capital Markets
  • IEEECharting the Energy Transition
  • Horizon 2045Future of Human and Planetary Security
  • WKOTechnology Scanning for Austria
audiences
  • Innovation
  • Strategy
  • Consultants
  • Foresight
  • Associations
  • Governments
resources
  • Pricing
  • Partners
  • How We Work
  • Data Visualization
  • Multi-Model Method
  • FAQ
  • Security & Privacy
about
  • Manifesto
  • Community
  • Events
  • Support
  • Contact
  • Login
ResearchServicesPricingPartnersAbout
ResearchServicesPricingPartnersAbout
  1. Home
  2. Research
  3. Helix
  4. Cellular Rejuvenation via Epigenetic Editing

Cellular Rejuvenation via Epigenetic Editing

Targeted editors restoring youthful epigenetic patterns.
Back to HelixView interactive version

Cellular rejuvenation via epigenetic editing uses targeted DNA methylation and demethylation editors (CRISPR-based systems that can add or remove methyl groups from DNA) to restore youthful epigenetic patterns in aged tissues like the retina, muscle, and liver, resetting the epigenetic clock (the pattern of DNA methylation that changes with age) to a younger state. By resetting epigenetic age, these therapies aim to restore youthful function to aged tissues and treat age-related diseases at their root cause, addressing the epigenetic changes that occur with aging. Companies and research institutions are developing these approaches.

This innovation addresses the role of epigenetic changes in aging, where DNA methylation patterns change with age and contribute to age-related dysfunction. By reversing these changes, epigenetic editing could potentially restore youthful function. The approach represents a targeted strategy for treating aging at the epigenetic level.

The technology is particularly significant for longevity medicine, where resetting epigenetic age could address multiple age-related conditions. As the technology improves, it could become an important tool for healthy aging. However, ensuring specificity, avoiding unintended effects, and demonstrating long-term benefits remain challenges. The technology represents an important approach to treating aging, but requires continued development and validation. Success could enable new treatments for age-related conditions by addressing aging at the epigenetic level, but the path to clinical use requires careful development to ensure safety and effectiveness.

TRL
5/9Validated
Impact
5/5
Investment
4/5
Category
Applications

Related Organizations

Altos Labs logo
Altos Labs

United States · Research Lab

100%

Biotechnology company focused on cellular rejuvenation programming.

Developer
Life Biosciences logo
Life Biosciences

United States · Company

95%

Developing therapeutics that target the biology of aging, including epigenetic reprogramming to restore visual function.

Developer
Retro Biosciences logo
Retro Biosciences

United States · Startup

95%

A startup with a mission to increase healthy human lifespan by ten years, focusing on cellular reprogramming, autophagy, and plasma-inspired therapeutics.

Developer
NewLimit logo
NewLimit

United States · Startup

90%

Co-founded by Brian Armstrong, focused on epigenetic reprogramming to restore youthful function to T-cells and other tissues.

Developer
Rejuvenate Bio logo
Rejuvenate Bio

United States · Startup

90%

Spinout from the Wyss Institute developing gene therapies for aging, including partial reprogramming strategies.

Developer
Salk Institute for Biological Studies logo
Salk Institute for Biological Studies

United States · Research Lab

90%

Home to the lab of Juan Carlos Izpisua Belmonte (prior to Altos), a pioneer in in-vivo partial reprogramming.

Researcher
Calico Life Sciences logo
Calico Life Sciences

United States · Company

85%

Alphabet-owned R&D company focused on the biology of aging, with active research into reprogramming biology.

Researcher
Shift Bioscience logo
Shift Bioscience

United Kingdom · Startup

85%

Uses AI to identify safe rejuvenation genes that can reset the epigenetic clock without causing cancer.

Developer

Supporting Evidence

Evidence data is not available for this technology yet.

Connections

Applications
Applications
Partial Reprogramming Therapies

Transient expression of Yamanaka factors targeting aging phenotypes.

TRL
4/9
Impact
5/5
Investment
5/5
Software
Software
Epigenetic Clock Algorithms

Machine learning models estimating biological age from methylation signatures.

TRL
6/9
Impact
4/5
Investment
4/5
Applications
Applications
Immune System Rejuvenation Therapies

Interventions targeting thymic involution and clonal hematopoiesis in aging.

TRL
4/9
Impact
5/5
Investment
3/5
Applications
Applications
Senolytics for Aging

Drug programs clearing senescent cells to delay multi-system decline.

TRL
5/9
Impact
5/5
Investment
4/5
Applications
Applications
Systemic Milieu Reset Protocols

Plasmapheresis and plasma-mimetic therapies to rebalance pro- and anti-aging factors.

TRL
4/9
Impact
4/5
Investment
4/5
Applications
Applications
Precision Longevity Interventions

Personalized stacks of therapeutics and lifestyle modifications.

TRL
7/9
Impact
4/5
Investment
4/5

Book a research session

Bring this signal into a focused decision sprint with analyst-led framing and synthesis.
Research Sessions